# BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

> **NCT07151690** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 21 (estimated)

## Conditions studied

- Systemic Light Chain Amyloidosis

## Interventions

- **DRUG:** anti-BCMA/CD3 bispecific antibody

## Key facts

- **NCT ID:** NCT07151690
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-04
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151690, "BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07151690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*